- Home
- MNRO vs CAPR Comparison
MNRO vs CAPR Comparison
Compare MNRO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNRO
- CAPR
- Stock Information
- Founded
- MNRO 1957
- CAPR 2005
- Country
- MNRO United States
- CAPR United States
- Employees
- MNRO N/A
- CAPR N/A
- Industry
- MNRO Automotive Aftermarket
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNRO Consumer Discretionary
- CAPR Health Care
- Exchange
- MNRO Nasdaq
- CAPR Nasdaq
- Market Cap
- MNRO 824.8M
- CAPR 867.6M
- IPO Year
- MNRO 1991
- CAPR N/A
- Fundamental
- Price
- MNRO $25.91
- CAPR $13.06
- Analyst Decision
- MNRO Hold
- CAPR Strong Buy
- Analyst Count
- MNRO 1
- CAPR 7
- Target Price
- MNRO $31.00
- CAPR $39.29
- AVG Volume (30 Days)
- MNRO 455.3K
- CAPR 1.5M
- Earning Date
- MNRO 01-22-2025
- CAPR 11-13-2024
- Dividend Yield
- MNRO 4.32%
- CAPR N/A
- EPS Growth
- MNRO N/A
- CAPR N/A
- EPS
- MNRO 0.86
- CAPR N/A
- Revenue
- MNRO $1,222,303,000.00
- CAPR $23,228,045.00
- Revenue This Year
- MNRO N/A
- CAPR N/A
- Revenue Next Year
- MNRO $3.09
- CAPR $74.85
- P/E Ratio
- MNRO $29.86
- CAPR N/A
- Revenue Growth
- MNRO N/A
- CAPR 65.33
- 52 Week Low
- MNRO $21.00
- CAPR $3.52
- 52 Week High
- MNRO $33.98
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- MNRO 38.77
- CAPR 37.54
- Support Level
- MNRO $25.69
- CAPR $13.00
- Resistance Level
- MNRO $27.98
- CAPR $20.75
- Average True Range (ATR)
- MNRO 0.74
- CAPR 1.60
- MACD
- MNRO -0.19
- CAPR -0.30
- Stochastic Oscillator
- MNRO 14.24
- CAPR 11.04
About MNRO Monro Inc.
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.